Nuvalent Granted FDA Breakthrough Therapy Designation for Non–Small Cell Lung Cancer Drug

NVL-520 is a novel, brain-penetrant, ROS1-selective tyrosine kinase inhibitor under evaluation for patients with metastatic ROS1-positive non–small cell lung cancer.

Source link
#Nuvalent #Granted #FDA #Breakthrough #Therapy #Designation #NonSmall #Cell #Lung #Cancer #Drug